Search Result for "*:*"
Clinical Trial

A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase – Chronic Myelogenous Leukemia (ASC2ESCALATE) (CTMS# 23-0101)

This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.

Story

Navigating the balancing act: Working while battling cancer

Receiving a cancer diagnosis introduces a myriad of challenges, with maintaining work commitments during treatment being a significant concern. However, it's possible to strike a balance between health and professional growth with the right strategies and support - this blog explores how.